This is a lot of technical jargon, but eventually it says that NeuralStem expects to be in clinical trials with a potential cure for PD within 14-18 months. Ron Reiner (50/3) -------------------------------------------------------------------- COLLEGE PARK, Md., May 19 /PRNewswire/ via NewsEdge Corporation -- NeuralSTEM Biopharmaceuticals, Ltd., today announced the issuance of U.S. Patent No. 5,753,506, a broad patent protecting the Company's proprietary CNS Stem Cell Technology. The technology is a breakthrough for cell-based genetic therapy and drug discovery aimed at disorders of the central nervous system (CNS) -- the brain and spinal cord. A pivotal development in the field of neuroscience, NeuralSTEM's technology enables the isolation, expansion, propagation in culture, and controlled differentiation of multipotential stem cells derived from the rodent or human fetal brain and spinal cord into the variety of neurons and glia that constitute the CNS. For the first time, this allows for the creation of the many different kinds of neurons found in the human brain; and enables their creation in commercially significant quantities, and under manipulable conditions. The patent claims are extremely broad and strong, garnering CNS stem cells from all fetal regions of the CNS, their derivatives, and their uses and products by process. "This patent firmly anchors NeuralSTEM's leading position in the development of novel biotherapeutics for neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease, as well as spinal cord injuries based upon CNS stem cell technology," said Richard Garr, President and CEO of NeuralSTEM. "In addition to our own therapeutic efforts, we believe that CNS stem cells will prove to be a universal delivery mechanism for all gene-based brain therapies." NeuralSTEM is pursuing commercial development of a new generation of cell-based genetic therapy products and therapeutics for CNS disorders and spinal cord injuries based upon the human neurons derived from its broad-platform stem cell technology. The Company's products in development will have the potential to replace, replenish and supplement nerve tissues. The CNS stem cell technology also allows for diverse human neurons produced in culture to be used in function-based live cell screens for traditional small-molecule drug discovery in the CNS area; and it will provide the basis for the Company's proprietary functional genomics projects. NeuralSTEM is currently negotiating strategic partnerships with several major pharmaceutical and biotechnology companies for development of its cell and gene therapies, functional genomics and drug discovery. Then Company expects to be in clinical trials with its lead program -- a novel Parkinson's disease cell therapy approach based on replacing damaged neurons with its stem cell-derived dopaminergic neurons -- within 14 to 18 months. NeuralSTEM Biopharmaceuticals, Ltd., is a privately held company engaged in research, development and commercialization of novel, proprietary therapeutics and technologies for the treatment and cure of neurodegenerative disorders of the brain and spinal cord, based upon the Company's patented CNS stem cell technology and human neurons derived from CNS stem cells. SOURCE NeuralSTEM Biopharmaceuticals, Ltd. /CONTACT: Richard Garr, President & CEO of NeuralSTEM Biopharmaceuticals, 301-571-9323; or Mary Moynihan of M2 Communications, 202-726-4800, for NeuralSTEM Biopharmaceuticals/